The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls

BMC Endocrine Disorders

Stephen L Atkin⁸  Khalid M Naseem²  Eric S Kilpatrick⁶  Ramzi A Ajjan⁷  Rebecca V Vince¹  Anne M Coady⁵  Alan S Rigby²  Tamas Ungvari³  Ahmed Aburima²  Hassan Kahal⁴ 

[1] Department of Sport, Exercise and Health Science, University of Hull, Hull, UK;Centre for Cardiovascular and Metabolic Research, Hull York Medical School, Hull, UK;Department of Cardiology, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK;Diabetes and Endocrinology, Diabetes Centre, York Hospital, Wigginton Road, York YO31 8HE, UK;Department of Radiology, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK;Clinical Biochemistry, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK;Division of Cardiovascular and Diabetes Research, Leeds Institute for Genetics, Health and Therapeutics, University of Leeds, Multidisciplinary Cardiovascular Research Centre, Leeds, UK;Weill Cornell Medical College Qatar, Doha, Qatar

关键词: Obesity;    cIMT;    Platelet function;    Liraglutide;    PCOS;   

Others  :  1161054
DOI  :  10.1186/s12902-015-0005-6

 received in 2014-01-28, accepted in 2015-02-18,  发布年份 2015

【 摘 要 】

Background

Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers. In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.

Methods

Carotid intima-media wall thickness (cIMT) was measured by B-mode ultrasonography, platelet function by flow cytometry, clot structure/lysis by turbidimetric assays and endothelial function by ELISA and post-ischaemic reactive hyperemia (RHI). Data presented as mean change (6-month – baseline) ± standard deviation.

Results

Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups. Twenty five (69.4%) participants completed the study (13 PCOS, 12 controls). At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56. Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline. Basal platelet P-selectin expression was significantly reduced at six months in controls −0.17 ± 0.26 but not PCOS −0.12 ± 0.28; between groups difference, 95% confidence interval = −0.14 – 0.26, P = 0.41. No significant changes were noted in cIMT or RHI.

Conclusions

Six months treatment with liraglutide (1.8 mg od) equally affected young obese women with PCOS and controls. In both groups, liraglutide treatment was associated with 3–4% weight loss and significant reduction in atherothrombosis markers including inflammation, endothelial function and clotting. Our data support the use of liraglutide as weight loss medication in simple obesity and suggest a potential beneficial effect on platelet function and atherothrombotic risk at 6 months of treatment.

Trial registration

Clinical trial reg. no. ISRCTN48560305 webcite. Date of registration 22/05/2012.

【 授权许可】

   
2015 Kahal et al.; licensee BioMed Central.

【 参考文献 】

• [1]Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al.: Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012, 97(1):28-38. e25
• [2]Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G: Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003, 18(9):1928-32.
• [3]Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ: Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001, 16(9):1995-8.
• [4]Meyer ML, Malek AM, Wild RA, Korytkowski MT, Talbott EO: Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2012, 18(2):112-26.
• [5]Dereli D, Ozgen G, Buyukkececi F, Guney E, Yilmaz C: Platelet dysfunction in lean women with polycystic ovary syndrome and association with insulin sensitivity. J Clin Endocrinol Metab 2003, 88(5):2263-8.
• [6]Rajendran S, Willoughby SR, Chan WP, Liberts EA, Heresztyn T, Saha M, et al.: Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 2009, 204(2):509-14.
• [7]Kahal H, Aburima A, Ungvari T, Rigby A, Dawson A, Coady A, et al.: Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. Clin Endocrinol (Oxf) 2013, 79(2):252-8.
• [8]Thomson RL, Brinkworth GD, Noakes M, Clifton PM, Norman RJ, Buckley JD: The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome. Hum Reprod 2012, 27(7):2169-76.
• [9]Russo I, Traversa M, Bonomo K, De Salve A, Mattiello L, Del Mese P, et al.: In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity (Silver Spring) 2010, 18(4):788-97.
• [10]Curioni CC, Lourenco PM: Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond) 2005, 29(10):1168-74.
• [11]Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R: Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008, 93(7):2670-8.
• [12]Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al.: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374(9683):39-47.
• [13]Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al.: Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374(9701):1606-16.
• [14]Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al.: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013, 37(11):1443-51.
• [15]Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod 2004, 19(1):41-7.
• [16]International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome [article online], 2006. 2006.
• [17]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-9.
• [18]Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al.: Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007, 23(1):75-80.
• [19]Riba R, Nicolaou A, Troxler M, Homer-Vaniasinkam S, Naseem KM: Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis 2004, 175(1):69-75.
• [20]Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A: Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004, 44(11):2137-41.
• [21]Alzahrani SH, Hess K, Price JF, Strachan M, Baxter PD, Cubbon R, et al.: Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab 2012, 97(12):E2282-7.
• [22]Hooper JM, Stuijver DJ, Orme SM, van Zaane B, Hess K, Gerdes VE, et al.: Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals. J Clin Endocrinol Metab 2012, 97(5):1463-73.
• [23]Noether GE: Sample Size Determination for Some Common Nonparametric Tests. J Am Stat Assoc 1987, 82(398):645-7.
• [24]Pasupathy S, Naseem KM, Homer-Vanniasinkam S: Effects of warm-up on exercise capacity, platelet activation and platelet-leucocyte aggregation in patients with claudication. Br J Surg 2005, 92(1):50-5.
• [25]Yamazaki M, Uchiyama S, Iwata M: Measurement of platelet fibrinogen binding and p-selectin expression by flow cytometry in patients with cerebral infarction. Thromb Res 2001, 104(3):197-205.
• [26]Engels JM, Diehr P: Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol 2003, 56(10):968-76.
• [27]Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, et al.: Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002, 288(16):2008-14.
• [28]Victoza 6 mg/ml solution for injection in pre-filled pen. http://www.medicines.org.uk/EMC/medicine/21986/SPC/Victoza+6+mg+ml+solution+for+injection+in+pre-filled+pen/ 05 April 2015.
• [29]van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH: Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014, 38(6):784-93.
• [30]Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brand CL, et al.: GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003, 140(1):123-32.
• [31]Bregenholt S, Moldrup A, Blume N, Karlsen AE, Nissen Friedrichsen B, Tornhave D, et al.: The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005, 330(2):577-84.
• [32]van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M: Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 2014, 221(1):T1-16.
• [33]Hsu-Lin S, Berman CL, Furie BC, August D, Furie B: A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets. J Biol Chem 1984, 259(14):9121-6.
• [34]Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, et al.: Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992, 359(6398):848-51.
• [35]Merten M, Thiagarajan P: P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000, 102(16):1931-6.
• [36]Hajek AS, Joist JH, Baker RK, Jarett L, Daughaday WH: Demonstration and partial characterization of insulin receptors in human platelets. J Clin Invest 1979, 63(5):1060-5.
• [37]Trovati M, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L, et al.: Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 1995, 44(11):1318-22.
• [38]Mertens I, Van Gaal LF: Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002, 3(2):85-101.
• [39]Orio F Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, et al.: Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005, 90(11):6072-6.
• [40]Lass N, Kleber M, Winkel K, Wunsch R, Reinehr T: Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab 2011, 96(11):3533-40.
• [41]Keogh JB, Brinkworth GD, Clifton PM: Effects of weight loss on a low-carbohydrate diet on flow-mediated dilatation, adhesion molecules and adiponectin. Br J Nutr 2007, 98(4):852-9.
• [42]Mohler ER 3rd, Sibley AA, Stein R, Davila-Roman D, Wyatt H, Badellino K, et al.: Endothelial function and weight loss: Comparison of low-carbohydrate and low-fat diets. Obesity (Silver Spring) 2013, 21(3):504-9.
• [43]Tschoner A, Sturm W, Gelsinger C, Ress C, Laimer M, Engl J, et al.: Long-term effects of pronounced weight loss after bariatric surgery on functional and structural markers of atherosclerosis. Obesity (Silver Spring) 2013, 21(10):1960-5.
• [44]Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, et al.: The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002, 283(4):E745-52.
• [45]Hucking K, Watanabe RM, Stefanovski D, Bergman RN: OGTT-derived measures of insulin sensitivity are confounded by factors other than insulin sensitivity itself. Obesity (Silver Spring) 2008, 16(8):1938-45.
• [46]Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 2004, 27(6):1487-95.
• [47]Diamanti-Kandarakis E, Dunaif A: Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012, 33(6):981-1030.
• [48]Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al.: GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58(4):975-83.